Company: MLTX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001821586-25-000018
Chunk: 23

Company: MoonLake Immunotherapeutics
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
5Three Months Ended June 30, 2024Six Months Ended June 30, 2025Six Months Ended June 30, 2024Service cost$83$68$159$139Interest cost881617Expected return on plan assets(20)(15)(39)(30)Amortization of unrecognized loss3365Prior service credit recognized in current year(3)(2)(5)(5)Net periodic benefit cost$71$62$137$126The components of net periodic benefit cost other than the service cost component are included in general and administrative expense in the Company's condensed consolidated statements of operations and comprehensive loss.Employer Contributions under the PlanFor the six months ended June 30, 2025, contributions of $146 thousand (CHF 126 thousand) were made to the Plan. The Company presently anticipates contributing an additional estimated amount of $146 thousand (CHF 126 thousand) to fund the Plan in 2025 for a total of $292 thousand (CHF 252 thousand)

Note 12 — Shareholders’ Equity

Class A Ordinary Shares(1)Class C Ordinary Shares(1)Total Number of Ordinary SharesAuthorizedIssued and OutstandingAuthorizedIssued and OutstandingAuthorizedIssued and OutstandingBalance at January 1, 2025500,000,00063,077,431100,000,000841,269600,000,00063,918,700Conversion of Class C Ordinary Shares into Class A Ordinary Shares—111,949—(111,949)——Option exercised and converted under the Employee Stock Option Plan—93,347———93,347Issuance of Restricted Stock Awards under the Equity Incentive Plan—191,526———191,526Balance at March 31, 2025500,000,00063,474,253100,000,000729,320600,000,00064,203,573Balance at June 30, 2025500,000,00063,474,253100,000,000729,320600,000,00064,203,573(1) Fully paid-in registered shares with a par value of $0.0001 

20

MOONLAKE IMMUNOTHERAPEUTICSNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2025(Unaudited)

Class A Ordinary SharesOn April 6, 2022, the Company's Class A Ordinary Shares began trading on The Nasdaq Capital Market